<ѻýҕl>Completely Oral Regimen Effective, Feasible in APLѻýҕl> 97% of patients alive and relapse-free at 3 years Dec 10, 2023
<ѻýҕl>Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin'sѻýҕl> 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022
<ѻýҕl>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCTѻýҕl> Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
<ѻýҕl>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLLѻýҕl> Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
<ѻýҕl>C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuriaѻýҕl> Iptacopan improved hemoglobin without transfusion versus current standard of care Dec 14, 2022
<ѻýҕl>High-Dose Chemo, ASCT Improves Survival in Primary CNS Lymphomaѻýҕl> European trial is "practice-changing as of today," says U.S. expert Dec 13, 2022
<ѻýҕl>Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibodyѻýҕl> Most complete responses lasted 24 months or longer after limited-duration glofitamab Dec 13, 2022
<ѻýҕl>Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALLѻýҕl> Phase III study showed 58% reduction in the risk of death versus chemo alone Dec 13, 2022
<ѻýҕl>Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Agingѻýҕl> Data from St. Jude cohort show higher rates of neurocognitive impairment Dec 13, 2022
<ѻýҕl>Heparin Fails to Stop Miscarriages in Women With Inherited Thrombophiliaѻýҕl> No difference in live birth rates with or without blood thinner Dec 13, 2022
<ѻýҕl>Durable Platelet Response in Immune Thrombocytopenia With Efgartigimodѻýҕl> Glycoprotein receptor inhibitor produces four times as many responses as placebo Dec 12, 2022
<ѻýҕl>Black Patients Less Likely to Get Advanced Treatments for PEѻýҕl> Also less likely for patients on Medicare and Medicaid Dec 12, 2022
<ѻýҕl>AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCTѻýҕl> Similar outcomes if patients went directly to transplant or received intensive salvage first Dec 11, 2022
<ѻýҕl>Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myelomaѻýҕl> Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients Dec 11, 2022
<ѻýҕl>Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphomaѻýҕl> Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone Dec 11, 2022
<ѻýҕl>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCTѻýҕl> "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<ѻýҕl>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemiaѻýҕl> OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
<ѻýҕl>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLLѻýҕl> Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
<ѻýҕl>Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphomaѻýҕl> Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
<ѻýҕl>Gene Therapy Resolves Severe Pain Events in Sickle Cell Diseaseѻýҕl> LentiGlobin also normalized hemoglobin and reduced hemolysis markers Dec 15, 2021
<ѻýҕl>Can Dasatinib Dose Be Halved in Low-Risk CML?ѻýҕl> Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
<ѻýҕl>CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCLѻýҕl> Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
<ѻýҕl>Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/Bѻýҕl> Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
<ѻýҕl>R-CHOP Toppled in First-Line DLBCL Trialѻýҕl> Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
<ѻýҕl>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALLѻýҕl> One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<ѻýҕl>β-Thalassemia Patients Go Transfusion-Free With Gene Therapyѻýҕl> Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
<ѻýҕl>R2 Maintenance for Elderly MCL Patients Worth the Risk?ѻýҕl> Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
<ѻýҕl>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Ratesѻýҕl> Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<ѻýҕl>Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphomaѻýҕl> Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021
<ѻýҕl>Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myelomaѻýҕl> Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
<ѻýҕl>CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphomaѻýҕl> Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
<ѻýҕl>Upfront IDH1 Inhibitor Triples Survival in Older AMLѻýҕl> Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
<ѻýҕl>Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Diseaseѻýҕl> Odronextamab, epcoritamab surpass 90% response threshold in early trials Dec 11, 2020
<ѻýҕl>Chemo-Free Combo Boosts PFS in First-Line CLLѻýҕl> PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting Dec 08, 2020
<ѻýҕl>Novel Agent Active in Refractory CMLѻýҕl> Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy Dec 08, 2020
<ѻýҕl>Gene Therapy Stops Bleeding in Hemophiliaѻýҕl> Single injection had durable effectiveness, study showed Dec 08, 2020
<ѻýҕl>Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLLѻýҕl> DFS at 1 year reaches 95% in patients with undetectable MRD Dec 06, 2020
<ѻýҕl>CRISPR-Based Tx Offers Hope in Tough-to-Treat Blood Disordersѻýҕl> Success with investigational use of gene editing in sickle cell disease, beta-thalassemia Dec 06, 2020
<ѻýҕl>Blood Cancers and COVID-19: 'A Medically Vulnerable' Groupѻýҕl> Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
<ѻýҕl>JAK Inhibitor Wins in Second-Line Chronic GVHDѻýҕl> Twice as many patients achieved a response at week 24 Dec 05, 2020